Published in Clin Cancer Res on May 01, 2000
Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther (2010) 1.29
Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J Immunother (2011) 1.00
Multimodal investigations of trans-endothelial cell trafficking under condition of disrupted blood-brain barrier integrity. BMC Neurosci (2010) 0.95
Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors. Neuro Oncol (2004) 0.88
Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination. Gene Ther (2013) 0.87
Potent Antitumor Activity Generated by a Novel Tumor Specific Cytotoxic T Cell. PLoS One (2013) 0.79
Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells. Oncotarget (2016) 0.76
Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci U S A (1979) 4.98
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 4.51
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med (2000) 4.50
Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. J Immunol (1992) 3.15
Identification of a human T lymphocyte surface protein associated with the E-rosette receptor. J Exp Med (1981) 3.06
Promoter region of interleukin-2 gene undergoes chromatin structure changes and confers inducibility on chloramphenicol acetyltransferase gene during activation of T cells. Mol Cell Biol (1986) 2.76
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Cytokine-dependent granulocytic differentiation. Regulation of proliferative and differentiative responses in a murine progenitor cell line. J Immunol (1987) 2.54
Surgical site infection after groin hernia repair. Br J Surg (2004) 2.54
Outcome of patients with severe chronic pain following repair of groin hernia. Br J Surg (2002) 2.38
Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med (1994) 2.29
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia (2009) 2.25
Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24
Breast MR imaging: interpretation model. Radiology (1997) 2.07
Cell-mediated cytotoxicity against virus-infected target cells in humans. II. Interferon induction and activation of natural killer cells. J Immunol (1978) 1.99
The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer (2001) 1.99
Groin hernia repair in Scotland. Br J Surg (2000) 1.93
Mechanisms of activation of human natural killer cells against tumor and virus-infected cells. Immunol Rev (1979) 1.88
Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol (1992) 1.88
Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology (1995) 1.84
Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG) Ann Intern Med (1994) 1.81
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia (2006) 1.79
Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood (1987) 1.77
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol (1997) 1.75
Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol (2000) 1.74
Should internal mammary lymph nodes in breast cancer be a target for the radiation oncologist? Int J Radiat Oncol Biol Phys (2000) 1.71
Spontaneous cell-mediated cytotoxicity in humans: role of interferon and immunoglobulins. J Immunol (1978) 1.71
Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol (2001) 1.70
Enhanced expression of HLA antigens and beta 2-microglobulin on interferon-treated human lymphoid cells. Eur J Immunol (1979) 1.65
Cell-mediated cytotoxicity against virus-infected target cells in humans. I. Characterization of the effector lymphocyte. J Immunol (1978) 1.58
Nonproductive infection of guinea pig cells with human cytomegalovirus. J Virol (1973) 1.56
HLA-related control of spontaneous and antibody-dependent cell-mediated cytotoxic activity in humans. J Immunol (1976) 1.54
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation (2001) 1.53
Tumour cell lines induce interferon in human lymphocytes. Nature (1977) 1.50
Direct agglutination test and other assays for measuring antibodies to Toxoplasma gondii. J Clin Pathol (1989) 1.49
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA (1999) 1.49
Erythrophagocytic T gamma lymphoma: a clinicopathologic entity resembling malignant histiocytosis. N Engl J Med (1981) 1.48
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia (2008) 1.46
Catamenial mononeuropathy and radiculopathy: a treatable neuropathic disorder. J Neurosurg (1998) 1.45
Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. J Exp Med (1992) 1.44
Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant (2003) 1.43
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol (2002) 1.42
Stimulation of Fc gamma RIIIA results in phospholipase C-gamma 1 tyrosine phosphorylation and p56lck activation. J Exp Med (1992) 1.41
A significant methotrexate-glutamine pharmacokinetic interaction. Nutrition (1995) 1.40
Laboratory medicine education in United States medical schools. Am J Clin Pathol (1993) 1.40
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy. Ann Oncol (1999) 1.40
Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy. Clin Lymphoma (2000) 1.39
Suppression of interleukin 2 receptor acquisition by monoclonal antibodies recognizing the 50 KD protein associated with the sheep erythrocyte receptor on human T lymphocytes. J Immunol (1985) 1.38
Discrepant toxoplasma latex agglutination test results. J Clin Pathol (1989) 1.37
Treatment of PTLD with rituximab or chemotherapy. Am J Transplant (2006) 1.33
Interleukin-3 regulates the activity of the LYN protein-tyrosine kinase in myeloid-committed leukemic cell lines. Blood (1992) 1.25
Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant (2007) 1.24
Imbalances in T cell subpopulations in multiple sclerosis patients. J Immunol (1978) 1.21
Immunoglobulin-A detection and the investigation of clinical toxoplasmosis. J Med Microbiol (1993) 1.20
A novel human T cell antigen preferentially expressed on mature T cells and shared by both well and poorly differentiated B cell leukemias and lymphomas. J Immunol (1981) 1.19
Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant (2006) 1.15
Spontaneous cell-mediated cytotoxicity in humans. Distribution and characterization of the effector cell. Clin Exp Immunol (1978) 1.15
High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol (1992) 1.15
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia (2002) 1.14
Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol (1999) 1.13
MR imaging-guided localization and biopsy of breast lesions: initial experience. Radiology (1994) 1.13
Identification and characterization of a low oxygen response element involved in the hypoxic induction of a family of Saccharomyces cerevisiae genes. Implications for the conservation of oxygen sensing in eukaryotes. J Biol Chem (2001) 1.11
Towards global analysis of mammalian proteomes using sample prefractionation prior to narrow pH range two-dimensional gels and using one-dimensional gels for insoluble and large proteins. Electrophoresis (2001) 1.11
Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis. J Immunol (1981) 1.09
Phosphatidylinositol-3 kinase activation induced upon Fc gamma RIIIA-ligand interaction. J Exp Med (1994) 1.08
EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant (2008) 1.08
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant (2008) 1.07
Alveolar macrophages, blood monocytes, and density-fractionated alveolar macrophages differ in their ability to promote lymphocyte proliferation to mitogen and antigen. Am Rev Respir Dis (1987) 1.07
Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. Am J Pathol (1998) 1.06
Two regions within the human IL-2 gene promoter are important for inducible IL-2 expression. J Immunol (1988) 1.06
Order of genes on human chromosome 5q with respect to 5q interstitial deletions. Am J Hum Genet (1990) 1.06
Hepatosplenic gammadelta T-cell lymphoma: ultrastructural, immunophenotypic, and functional evidence for cytotoxic T lymphocyte differentiation. Hum Pathol (1997) 1.05
Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★). Am J Transplant (2011) 1.04
Human T-lymphocyte subpopulations: alterations in systemic lupus erythematosus. Scand J Immunol (1979) 1.04
Functional correlation between antibody-dependent and spontaneous cytotoxic activity of human lymphocytes and possibility of an HLA-related control. Transplant Proc (1977) 1.04
Local recurrence of breast cancer in the stereotactic core needle biopsy site: case reports and review of the literature. Breast J (2001) 1.03
Diagnostic performance characteristics of architectural features revealed by high spatial-resolution MR imaging of the breast. AJR Am J Roentgenol (1997) 1.01
Center-defined unacceptable HLA antigens facilitate transplants for sensitized patients in a multi-center kidney exchange program. Am J Transplant (2014) 1.01
Functional properties of the 50 kd protein associated with the E-receptor on human T lymphocytes: suppression of IL 2 production by anti-p50 monoclonal antibodies. J Immunol (1985) 0.99
High-dose cytarabine neurotoxicity: MR findings during the acute phase. AJNR Am J Neuroradiol (1993) 0.98
Arginine at positions 13 or 70-71 in pocket 4 of HLA-DRB1 alleles is associated with susceptibility to tuberculoid leprosy. J Exp Med (1996) 0.97
An improved in situ hybridization method. Exp Cell Res (1978) 0.96
Feeding by tube enterostomy. Surg Gynecol Obstet (1980) 0.96
High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplant (2012) 0.96